Cite
HARVARD Citation
Schöffski, P. et al. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for immunotherapy of cancer. 10 (2), p. . [Online].